Serologic cross-reactivity among allelic gene products commonly occurs in the HLA complex, but the molecular basis of these serologic phenomena is incompletely characterized. Because of strong cross-reactivity among antigens comprising the B7 cross-reactive group (i.e., HLA-B7, Bw22, B27, B40, and Bw42) and because of the association of several antigens of this group with spondyloarthropathies, we initiated a study of the chemical basis of cross-reactivity among this group of antigens. Using classic serologic procedures, 125I-Protein A binding assay, and chemical immunoprecipitation techniques, we have defined a new antigenic determinant, tentatively designated "X", which is present on certain HLA-B molecules. By a series of sequential immunoprecipitation experiments, X was shown to be a "public" antigenic determinant distinct from the "private" determinants B7, Bw22, B27, and B40, but present on the same 44,000-dalton glycoprotein molecules. The implications of this finding regarding disease predisposition and HLA typing as a diagnostic aid are discussed.
B D Schwartz, L K Luehrman, G E Rodey
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.